Table 3 Treatment group B: 0.3 mg/kg.

From: Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

  1. Echocardiographic variables for the 0.3 mg/kg aficamten treatment group with reported mean ± standard deviation (unshaded rows) and median and interquartile range (shaded rows). The Pvalue for variables that were statistically evaluated by either repeated measures one-way ANOVA or Friedman’s test are shown.
  2. LA left atrium, LVIDd left ventricular internal dimensions (diastole), LVIDs left ventricular internal dimensions (systole), LV left ventricle, FS fractional shortening, LVIDd left ventricular internal diameter (diastole), LVIDs left ventricular internal diameter (systole), LA/Ao left atrial-to-aortic root ratio, LVOT left ventricular outflow tract, Vmax velocity (maximum), PG pressure gradient, HR heart rate, IVRT isovolumic relaxation time, TD tissue Doppler, S’ mitral annular systolic velocity, MAPSE mitral annular plane systolic excursion, TAPSE tricuspid annular plane systolic excursion.
Back to article page